Authors
John C Woodfield, Kari A Clifford, Rohan Thomas, Simon J G Richards, Anna Kate Fowler, Mohammad K Alquassab, Chrissie Roodt, Mark W Thompson-Fawcett
Published in
BJS open. Volume 10. Issue 6. Nov 03, 2026.
Abstract
Major low anterior resection syndrome (LARS) affects approximately 60% of rectal cancer survivors, causing urgency and decreased bowel control, reducing quality of life. Bile acid malabsorption (BAM) is an under-recognized contributor whose prevalence and treatment efficacy remain unclear. This proof-of-concept study evaluated the effectiveness of colesevelam for treating LARS and described the prevalence of BAM.
This double-blind randomized placebo-controlled crossover trial was conducted between 2021 and 2024 in New Zealand. Adults aged 18-85 years with major LARS received colesevelam (up to 1.25 g, three times daily) or placebo for 5 weeks, separated by a 6-week washout period. A subset of patients underwent 75-selenium homocholic acid taurine (SeHCAT) testing for BAM. The outcomes of interest included changes in the LARS score, Fecal Incontinence Quality of Life Scale (FIQL), and Short-Form 12 (SF-12) questionnaire, with a composite outcome reflecting clinically important improvements.
Of 80 eligible patients, 49 were randomized. However, 36 patients completed the study after washout and were included in a per-protocol analysis (mean age 71 years; 69% male). In these 36 patients, colesevelam did not significantly improve LARS scores, but did significantly improve the SF-12 mental component summary (median +2.36; 95% confidence interval 0.00 to 10.25; P < 0.01) and FIQL depression/self-perception. Eight of 19 patients (42%) had BAM and exhibited significant improvements in SF-12 physical and mental item scores with colesevelam. Using composite criteria, colesevelam produced a 33% response rate, versus 8% for placebo, with higher rates in BAM-positive (50%) than BAM-negative (11%) patients.
BAM is a treatable contributor to LARS, present in 40% of tested patients. Although treating all LARS patients with bile acid sequestrants provides limited benefit, SeHCAT testing identifies patients likely to respond. BAM assessment would be beneficial if incorporated into LARS management.
PMID:
43023689
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0